Theravance Biopharma (TBPH) Earning Somewhat Favorable Media Coverage, Report Shows
Media stories about Theravance Biopharma (NASDAQ:TBPH) have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Theravance Biopharma earned a news impact score of 0.13 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.6078743661376 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
- Zacks: Analysts Expect Theravance Biopharma, Inc. (NASDAQ:TBPH) Will Announce Quarterly Sales of $3.59 Million (americanbankingnews.com)
- See what the IHS Markit Score report has to say about Theravance Biopharma Inc. (finance.yahoo.com)
- Theravance Biopharma, Inc. (NASDAQ:TBPH) Director Buys $143,940.00 in Stock (americanbankingnews.com)
- Theravance Biopharma, Inc. (NASDAQ:TBPH) CEO Rick E. Winningham Purchases 10,000 Shares (americanbankingnews.com)
- Q3 2017 EPS Estimates for Theravance Biopharma, Inc. Decreased by Analyst (NASDAQ:TBPH) (americanbankingnews.com)
Shares of Theravance Biopharma (TBPH) opened at 24.10 on Friday. The stock has a 50 day moving average price of $35.84 and a 200-day moving average price of $35.42. The company’s market cap is $1.30 billion. Theravance Biopharma has a 1-year low of $23.15 and a 1-year high of $43.44.
Several equities research analysts have issued reports on the company. BidaskClub lowered Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Cantor Fitzgerald set a $55.00 price target on Theravance Biopharma and gave the stock a “buy” rating in a research note on Wednesday, July 19th. Needham & Company LLC boosted their target price on Theravance Biopharma from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, May 11th. Leerink Swann set a $47.00 target price on Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday, May 10th. Finally, ValuEngine lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Four research analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. Theravance Biopharma currently has a consensus rating of “Hold” and a consensus target price of $41.13.
TRADEMARK VIOLATION NOTICE: This report was posted by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/theravance-biopharma-tbph-earning-somewhat-favorable-media-coverage-report-shows/1480246.html.
In other news, CEO Rick E. Winningham acquired 10,000 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was acquired at an average price of $24.50 per share, with a total value of $245,000.00. Following the completion of the purchase, the chief executive officer now directly owns 866,377 shares in the company, valued at $21,226,236.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Henrietta Fore acquired 6,000 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was purchased at an average cost of $23.99 per share, with a total value of $143,940.00. Following the purchase, the director now owns 24,000 shares of the company’s stock, valued at $575,760. The disclosure for this purchase can be found here. 6.10% of the stock is owned by company insiders.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.